SMAD3 and Hepatic fibrosis: Mechanistic studies have revealed that SIRT6 inhibits TGF-β-induced activation of hepatic stellate cells by deacetylating specific sites (K333 and K378) on Smad3, resulting in the downregulation of liver fibrosis-related genes and the inhibition of fibrosis progression [125].